Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Confirmed squamous cell carcinoma (SCC) of the head and neck (oropharynx, oral cavity, hypopharynx, or larynx) or skin * For patients with oropharyngeal cancer, p16 status is known or can be determined * Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) * Acceptable laboratory results as indicated by protocol * Acceptable cardiac function as indicated by protocol Exclusion Criteria: * Received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy for recurrent or metastatic Squamous Cell Carcinoma (e.g., oral EGFR TKIs such as erlotinib, gefitinib, or afatinib) * Family history of long corrected QT interval (QTc) syndrome * Receiving medication that prolongs QT interval ,with a risk of causing Torsades de Pointes (TdP), unless ECG meets inclusion criteria while on a stable dose of the medication * Family history of long QTc syndrome * Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy * Radiation therapy within 2 weeks prior to the first dose of study medication * Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication * Concurrent active malignancy requiring systemic treatment * Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection * Pregnant or breast-feeding